Searched for
ABRAXIS BIOSCIENCES
After Market: SPARC rallies 5%; PCJ, YES Bank sink; 57 stocks turn oversoldNifty Midcap index shed 1.28% to 16,512 while Nifty Smallcap index dipped 1.13% to 5,590.- US company Abraxis BioSciences denied patent on anti-cancer drugThe application was refused on the grounds of the US firm's claims lacking of inventive step, not being patentable and insufficiency, legal...
- Panacea Biotec to launch breast cancer drugPanacea Biotec will soon launch a generic version of Abraxis Bioscience's breast cancer medicine Abraxane at half the price of the original...
- Sanofi plans mega US deal to counter sales dipSanofi-Aventis, France’s biggest drugmaker, is preparing a major acquisition in the US, according to five people with knowledge of the situ...
- Natco to launch cancer drug as min stays DCGI orderThe original maker of the drug, American firm Abraxis Bioscience had complained about the side effects of Natco’s version of the medicine.
- Natco Pharma faces criminal actionThe country’s top drug regulator plans to initiate criminal proceedings against Hyderabad-based Natco Pharma for selling “substandard” brea...
- Govt orders recall as Natco cancer drug fails toxin testThe drug regulator (DCGI) acted afer the US firm filed a written complaint citing serious side-effects that the generic may cause.
- Biocon launches breast cancer drugBiotech company Biocon said it has launched the drug Abraxane, used in the treatment of breast cancer.
- Biocon receives DCGI nod to market AbraxaneLeading biotech company Biocon Ltd has received approval from the Drug Controller General of India (DCGI) to market breast cancer drug Abra...
- Biocon scouting for buyouts to boost businessBiocon Ltd may list its shares on international bourses in its effort to strengthen its pharmaceutical business.
- Biocon to market Abraxis' breast cancer drug in IndiaBiocon Ltd on Thursday announced it has entered into a licensing agreement with US-based Abraxis BioScience Inc for selling 'Abraxane' in I...
- Biocon to develop neutropenia drug with US companyBiocon on Thursday said it will develop a drug for treatment of neutropenia, which refers to lowering of white blood cells count in the bod...
Load More- Sanofi plans mega US deal to counter sales dip
